Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:53 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 6,440 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Clear all
Active, not recruiting No phase listed Observational

AKI and Delirium Risk Prediction and Cost Burden Study

NCT07866560
View directory record Official record
Conditions
Acute Kidney Injury, Delirium
Interventions
It is observational trial with no intervention being evaluated
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
25,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 2, 2026, 5:53 AM EST
Completed Phase 2 Interventional Results available

Study of Phosphate Levels in Patients With Chronic Kidney Disease

NCT00824460
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
1.25 g PA21 (250 mg iron), 5.0 g PA21 (1,000 mg iron), 7.5 g PA21 (1,500 mg iron), 10.0 g PA21 (2,000 mg iron), 12.5 g PA21 (2,500 mg iron), Sevelamer hydrochloride
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Arvada, Colorado • Denver, Colorado • Pembroke Pines, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Nov 2, 2026, 5:53 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

NCT06397872
View directory record Official record
Conditions
Renal Impairment
Interventions
100 mg Resmetirom Tablet
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Orlando, Florida • Tampa, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Nov 2, 2026, 5:53 AM EST
Completed Not applicable Interventional Results available

Stress and CKD Among African Americans

NCT03387319
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Racialized Stressful Event Recall, Non-Racialized Stressful Event Recall
Behavioral
Lead sponsor
Emory University
Other
Eligibility
25 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Nov 2, 2026, 5:53 AM EST
Terminated Not applicable Interventional Results available

LoBAG30 Diet in Patients on Metformin

NCT00607867
View directory record Official record
Conditions
Diabetes Mellitus, Diet
Interventions
LoBAG30 diet, Control Diet
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2014 · Synced Nov 2, 2026, 5:53 AM EST
Terminated Phase 1 Interventional

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors

NCT04301011
View directory record Official record
Conditions
Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer, Melanoma (Skin), Cutaneous Squamous Cell Carcinoma, Mesothelioma, Renal Cell Carcinoma, Oropharynx Cancer
Interventions
TBio-6517, Pembrolizumab
Biological
Lead sponsor
Turnstone Biologics, Corp.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Nov 2, 2026, 5:53 AM EST
Recruiting Phase 2 Interventional

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants

NCT07494045
View directory record Official record
Conditions
CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
Interventions
CTAP101
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
1 Month to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Kansas City, Missouri • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 2, 2026, 5:53 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

NCT02160145
View directory record Official record
Conditions
Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease
Interventions
Tolvaptan (OPC-41061), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
82
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Nov 2, 2026, 5:53 AM EST
Completed No phase listed Observational Results available

Inferior Vena cavaCollapsibility Index in Patients With Acute Kidney Injury

NCT02165072
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Nov 2, 2026, 5:53 AM EST
Completed Not applicable Interventional

SUSTAIN: Behavior Change and Nutrition Security for CKMS

NCT06589336
View directory record Official record
Conditions
Stage 2 Cardiovascular-Kidney-Metabolic Syndrome, Cardiovascular Disease Other
Interventions
Dietary changes via Instacart vouchers, Dietary changes via access to Mid-Ohio Farmacy, Behavior changes via access to Health Impact Ohio Hub, Behavioral nutrition counseling, Cooking classes, Dietary changes to Delivery fees
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Nov 2, 2026, 5:53 AM EST
Terminated Phase 3 Interventional

A Study To Test An Anti-Rejection Therapy After Kidney Transplantation

NCT00000936
View directory record Official record
Conditions
Kidney Transplantation
Interventions
hOKT3, Oral Cyclosporine, IV Cyclosporine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 20 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Nov 2, 2026, 5:53 AM EST
Completed Not applicable Interventional Results available

Impact of Vitamin D Repletion in Hemodialysis Patients

NCT01175798
View directory record Official record
Conditions
Vitamin D Deficiency, End-stage Renal Disease
Interventions
Cholecalciferol
Drug
Lead sponsor
Mehrotra, Anita, M.D.
Individual
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Nov 2, 2026, 5:53 AM EST
Completed Not applicable Interventional

Study of Home-Embedded Palliative Care for Hemodialysis-Dependent End-Stage Renal Disease

NCT05471622
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Nudge for PHPC Referral
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Nov 2, 2026, 5:53 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters

NCT05365451
View directory record Official record
Conditions
Interaction, Endogenous Biomarkers
Interventions
MetFORMIN Oral Solution, Cimetidine 400 MG, Furosemide Oral Liquid Product, Probenecid 500 MG
Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Nov 2, 2026, 5:53 AM EST
Completed Phase 4 Interventional Results available

A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)

NCT02576145
View directory record Official record
Conditions
Kidney Transplantation
Interventions
DT, Daclizumab, KLH
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 19 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
5
States / cities
Los Angeles, California • Indianapolis, Indiana • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Nov 2, 2026, 5:53 AM EST
Completed Phase 2 Interventional

Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients

NCT02251067
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
VPI-2690B low dose, VPI-2690B medium dose, Placebo to match VPI-2690B, VPI-2690B high dose
Drug
Lead sponsor
Vascular Pharmaceuticals, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Nov 2, 2026, 5:53 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

NCT07293351
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma (RCC)
Interventions
Pumitamig, Ipilimumab, Cabozantinib, Casdatifan
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
17
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 2, 2026, 5:53 AM EST
Withdrawn Not applicable Interventional

Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI

NCT05114057
View directory record Official record
Conditions
Acute Kidney Injury, Acute Kidney Injury Due to Sepsis, Neonatal Sepsis
Interventions
Renal Angina Index (RAI)
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Nov 2, 2026, 5:53 AM EST
Terminated No phase listed Observational

Genetic Susceptibility to Kidney Cancer

NCT00854022
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Nov 2, 2026, 5:53 AM EST
Completed Phase 3 Interventional Results available

Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer

NCT00087022
View directory record Official record
Conditions
Kidney Cancer
Interventions
girentuximab, placebo
Biological · Other
Lead sponsor
Heidelberg Pharma AG
Industry
Eligibility
18 Years to 120 Years
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
39
States / cities
Anchorage, Alaska • Los Angeles, California • San Francisco, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Nov 2, 2026, 5:53 AM EST
Completed No phase listed Observational

Delaying the Progression of Diabetic Nephropathy in Pima Indians

NCT00353600
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 2, 2026, 5:53 AM EST
Completed Phase 1 Interventional

Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets

NCT00195936
View directory record Official record
Conditions
Hypophosphatemic Rickets, X-Linked Dominant
Interventions
Cinacalcet
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
5 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Nov 2, 2026, 5:53 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

NCT05099445
View directory record Official record
Conditions
Renal Impairment, Hemodialysis
Interventions
INCB000928
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 82 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
5
States / cities
Rialto, California • Hialeah, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Nov 2, 2026, 5:53 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

NCT01240967
View directory record Official record
Conditions
Healthy Volunteers, Patients, Pharmacokinetics, Renal Impairment
Interventions
TC-5214
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Nov 2, 2026, 5:53 AM EST